Aug 20 (Reuters) - British drugmaker AstraZeneca Plcsaid on Tuesday that its diabetes drug Farxiga met the main goalof a late-stage study for the treatment of patients with heartfailure.
Farxiga was successful in reducing the risk ofcardiovascular death or the worsening of heart failure when usedalong with the standard treatment in the DAPA-HF trial, thecompany said in a statement.(Reporting by Pushkala Aripaka in Bengaluru; editing by PatrickGraham)